Clinical trials: FSGS
Focal Segmental Glomerulosclerosis, Minimal Change Disease
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
The morbidity of recurrence of focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) after transplant is well-recognized and include contemporary reduction in quality of life, edema, early graft loss and…
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, FSGS, MCD
- Trial name
- RESOLVE (NCT05650619)
- Testing
- Biospecimen collection, Data collection
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Michigan
Kidney Diseases
Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH
FSGS is an immunologic disorder wherein circulating immune proteins cause damage to the kidneys and progressive injury and scarring.
- Trial name
- NCT01155141
- Testing
- H.P. Acthar Gel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Stanford University
Focal Segmental Glomerulosclerosis, Minimal Change Disease
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis
- Trial name
- EPPIK (NCT05003986)
- Testing
- Sparsentan
- Where
- 47 sites in United States, Germany and 6 more
- Volunteers
- 67 people
- Sponsor
- Travere Therapeutics, Inc.
Fluid Overload, Glomerulosclerosis, Focal Segmental
Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
Researchers from the University of Michigan and Northwestern University are studying people's experiences with swelling caused by Nephrotic Syndrome.
- Conditions
- Fluid Overload, Glomerulosclerosis, Focal Segmental, Edema, Membranous Nephropathy
- Trial name
- Prepare-NS (NCT05505500)
- Testing
- Interview
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Michigan
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including…
- Conditions
- Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- MERIT (NCT07892651)
- Where
- Jordan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Axiom Bioregistry
SIOD, Cystinosis
Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor
This is a single center, non-randomized, non-controlled open-label phase 1b/2a trial of performing sequential αβdepleted-HSCT and KT in patients requiring KT to prevent kidney rejection post-KT, in the absence of any post-KT…
- Conditions
- SIOD, Cystinosis, FSGS, SLE Nephritis
- Trial name
- NCT05508009
- Testing
- Cyclophosphamide 1200 mg/Kg, Fludarabine, Cyclophosphamide 100 mg/Kg
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Alice Bertaina
Nephrotic Syndrome in Children, Focal Segmental Glomerulosclerosis
NEPTUNE Match Study
NEPTUNE Match is an additional opportunity offered to NEPTUNE study participants to prospectively recruit and communicate patient-specific clinical trial matching with kidney patients and their physician investigators.
- Conditions
- Nephrotic Syndrome in Children, Focal Segmental Glomerulosclerosis, Minimal Change Disease, Minimal Change Nephrotic Syndrome
- Trial name
- NEPTUNE Match (NCT04571658)
- Testing
- Communication
- Where
- 16 sites in United States
- Volunteers
- 375 people
- Sponsor
- University of Michigan
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
Focal Segmental Glomerulosclerosis
LDL-Apheresis for FSGS CardioRenal Outcomes
Focal segmental glomerulosclerosis (FSGS) is the most common cause of end-stage renal disease (ESRD) in adolescents. The refractory nature of FSGS and a more than 30% recurrence rate after kidney transplantation renders treatment…
- Trial name
- NCT04088799
- Testing
- No intervention
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Primary Focal Segmental Glomerulosclerosis
A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS
The purpose of this study is to determine whether Rituximab therapy is safe and effective in treating patients with the kidney condition, focal segmental glomerulosclerosis (FSGS), that is no longer responsive to traditional…
- Trial name
- NCT01573533
- Testing
- Rituximab
- Where
- 4 sites in United States, Canada
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Focal Segmental Glomerulosclerosis
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
Liposorber® LA-15 System is a blood purification therapy that selectively removes malignant lipoproteins including low density lipoprotein from circulating blood flow and rapidly reduces the plasma cholesterol level.
- Trial name
- FSGS pediatric (NCT02235857)
- Testing
- LIPOSORBER® LA-15 System
- Where
- 12 sites in United States
- Volunteers
- 35 people
- Sponsor
- Kaneka Medical America LLC
FSGS, Proteinuria
Rituximab to Prevent Recurrence of Proteinuria
The investigators propose to study novel targets of rituximab in podocytes, with a particular focus on recurrent focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT01164098
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- George W. Burke
Nephrotic Syndrome in Children, Minimal Change Disease
A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)
Children with steroid resistant nephrotic syndrome (SRNS) are exposed to prolonged courses of immunosuppressant medications. Given the adverse side effect profiles and variable efficacy of these medications, there is an urgent…
- Conditions
- Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
- Trial name
- kidNEY-VNS (NCT05583942)
- Testing
- trascutaneous auricular vagus nerve stimulation
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Northwell Health
Kidney Diseases
China Kidney Patient Trials Network
This is a prospective multi-centre, observational cohort study of incident and prevalent patients diagnosed with a kidney disease in China.
- Trial name
- CKPTN (NCT05036850)
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- George (Beijing) Clinical Research Co. Ltd.
IgA Nephropathy (IgAN), Membranous Nephropathy
Raman Spectroscopy Diagnosis of Kidney Diseases
This research plan, from January 2021 to December 2024, aims to collect serum and morning urine from patients diagnosed with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy, and focal segmental…
- Conditions
- IgA Nephropathy (IgAN), Membranous Nephropathy, Diabetic Nephropathy, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- NCT06760845
- Testing
- Imaging Time
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Zunsong Wang
Minimal Change Disease (MCD), Membranous Nephropathy
Nephrotic Syndrome Study Network
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage…
- Conditions
- Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
- Trial name
- NEPTUNE (NCT01209000)
- Testing
- Kidney Biopsy
- Where
- 44 sites in United States, Canada
- Volunteers
- 1,200 people
- Sponsor
- University of Michigan
Focal Segmental Glomerulosclerosis
Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor
This study is a proof-of-concept clinical study designed to test the hypothesis that oral administration of galactose can lower the level of a circulating factor that increases glomerular permeability to albumin in patients with…
- Trial name
- NCT00816478
- Testing
- Galactose
- Volunteers
- 15 people
- Sponsor
- Northwell Health
pMN, IgAN
Atacicept in Multiple Glomerular Diseases
A study to find how well atacicept works and how safe it is in participants with autoimmune kidney disease.
- Conditions
- pMN, IgAN, Nephrotic Syndrome, MCD
- Trial name
- NCT06983028
- Testing
- Atacicept
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Vera Therapeutics, Inc.
HIV-Associated Focal Segmental Glomerulosclerosis, HIV-Associated Collapsing Glomerulopathy
Evaluation of Albuminuria HIV-Infected Patients
This study will examine the following: 1) how common albuminuria and proteinuria are among HIV-positive patients, 2) what causes albuminuria or proteinuria in these patients and 3) whether the condition becomes more severe over…
- Conditions
- HIV-Associated Focal Segmental Glomerulosclerosis, HIV-Associated Collapsing Glomerulopathy, Proteinuria, Albuminuria
- Trial name
- NCT00524992
- Where
- 2 sites in United States
- Volunteers
- 252 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
FSGS
The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis
This is a prospective,multicentre study to compare the efficacy, safety, tolerability and relapse of FK506 versus CTX in the treatment of severe Focal Segmental Glomerulosclerosis (FSGS).
- Trial name
- FSGS (NCT01451489)
- Testing
- FK506, Cyclophosphamide
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Nanjing University School of Medicine